A61K 2039/55538
Il-12
Official title: {il-12}
A61K2039/55538 (Il-12) appears on 180 US grants and 329 published applications in this corpus.
Search patents in A61K- Granted patents
- 180
- Published applications
- 329
- Assignees
- 134
- Inventors
- 491
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 2 |
| 2002 | 4 | 6 |
| 2003 | 0 | 5 |
| 2004 | 4 | 6 |
| 2005 | 3 | 10 |
| 2006 | 2 | 7 |
| 2007 | 0 | 10 |
| 2008 | 3 | 4 |
| 2009 | 2 | 5 |
| 2010 | 2 | 8 |
| 2011 | 1 | 7 |
| 2012 | 4 | 5 |
| 2013 | 4 | 10 |
| 2014 | 5 | 10 |
| 2015 | 6 | 7 |
| 2016 | 8 | 11 |
| 2017 | 7 | 3 |
| 2018 | 5 | 9 |
| 2019 | 2 | 15 |
| 2020 | 31 | 49 |
| 2021 | 38 | 34 |
| 2022 | 11 | 23 |
| 2023 | 6 | 29 |
| 2024 | 13 | 15 |
| 2025 | 6 | 27 |
| 2026 | 2 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions comprising non-immunogenic RNA encoding immunogenic epitopes and interferon alpha14 Jul 2026US 12,678,497 B2BioNTech SE
- All-in one vector for CAR and therapeutic effector molecule26 May 2026US 12,637,694 B2Medizinische Hochschule Hannover
- Vaccine compositions and methods for the treatment and prevention of urinary tract infections9 Dec 2025US 12,491,237 B2Duke University
- Vaccines for recurrent respiratory papillomatosis and methods of using the same25 Nov 2025US 12,478,667 B2Inovio Pharmaceuticals, Inc.
- MRNA treatment nanoparticles18 Nov 2025US 12,473,554 B2Nutcracker Therapeutics, Inc.
- Treatment involving non-immunogenic rna for antigen vaccination8 Oct 2026US 2026/0306625 A1BioNTech SE
- Hiv immunogenic polypeptides and vaccines and uses thereof24 Sep 2026US 2026/0284175 A1Gilead Sciences, Inc.
- Dual-germline antibody engager hiv-1 envelope chimeric immunogens27 Aug 2026US 2026/0248907 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
- Tumor cell vaccines20 Aug 2026US 2026/0240969 A1Neuvogen, Inc.
- Enhanced adoptive cell therapy16 Jul 2026US 2026/0199433 A1Werewolf Therapeutics, Inc.
Most cited
By later US patents
- Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines290US 6,218,371 B1University of Iowa Research Foundation · 2001
- Compositions and methods for use of IL-12 as an adjuvant75US 5,723,127 AThe Trustees of the University of Pennsylvania · 1998
- RNA containing composition for treatment of tumor diseases49US 10,293,058 B2CureVac AG · 2019
- Compositions and methods for use of IL-12 as an adjuvant44US 5,571,515 AThe Trustees of the University of Pennsylvania · 1996
- RNA containing composition for treatment of tumor diseases39US 10,918,740 B2CureVac AG · 2021